Each tablet contains Oxcarbazepine 150 mg / 300mg /600mg.
As monotherapy & adjunct therapy in treatment of partial seizures in adult patients with epilepsy.Treatment of generalized tonic-clonic seizures in adults and children, Monotherapy in the treatment of partial seizures in children aged4-16 years.
The pharmacological activity of Oxcarbazepine is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine. Produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses.
Adults: Initiate with a dose of 600 mg/day, given twice-a-day. Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals. The recommended daily dose is 1200 mg/day. Conversion to Monotherapy: withdrawal concomitant over 3 to 6 weeks; reach maximum dose of Carbox in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/day. Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1200 mg/day. Initiate at one-half the usual starting dose and increase slowly in patients with a creatinine clearance. Pediatrics: initiation with 8 to 10 mg/kg/day, given twice-a-day. Conversion to Monotherapy for Patients (Aged 4–16 Years) Maximum increment of 10 mg/kg/day at weekly intervals, concomitant antiepileptic drugs can be completely withdrawn over 3 to 6 weeks. Initiation of Monotherapy for Patients (Aged 4–16 Years): Increments of 5 mg/kg/day every third day.
Contraindicated in patients with known hypersensitivity to oxcarbazepine
Hyponatremia-monitor sodium, anaphylactic reactions and angioedema(discontinue if occurs). Patients with a past history of hypersensitivity reaction to Carbamazepine- only use based upon risk benefit, serious dermatological reactions- discontinue if observed, suicidal behavior and ideation- monitor for symptoms,withdraw gradually, multi-organ hypersensitivity- discontinue if suspected.
Pregnancy Category C. There are no adequate and well-controlled studies on safety and effectiveness of Oxcarbazepine in pregnancy and nursing.The short term use in pediatric patients aged 6-16 years with partial onset seizures is supported and is not approved in pediatric patients in less than 6 years of age.
Phenytoin, Carbamazepine, and Phenobarbital: Co-administration decreases blood levels of Oxcarbazepine greater dose may be required. Hormonal contraceptives: oxcarbazepine may render them infective.
Most commonly adverse reactions are dizziness, somnolence, headache, balance disorder, tremor, vomiting, diplopia, asthenia, and fatigue.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS